For AML, gemtuzumab ozogamicin, an antibody against CD33 conjugated to the chemotherapy calicheamicin, has been evaluated as a maintenance treatment with azacitidine after HSCT in a small series of 10 AML adult patients. Here, CD33 is linked to acute myeloid leukemia.